These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 15481207)

  • 41. BCG in Finland: changing from a universal to a selected programme.
    Salo EP
    Euro Surveill; 2006; 11(3):18-20. PubMed ID: 16567879
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunisation coverage and its associations in rural Tanzanian infants.
    Kruger C; Olsen OE; Mighay E; Ali M
    Rural Remote Health; 2013; 13(4):2457. PubMed ID: 24215438
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The real-life number of neonatal doses of Bacille Calmette-Guérin vaccine in a 20-dose vial.
    Schaltz-Buchholzer F; Frankel HN; Benn CS
    Glob Health Action; 2017; 10(1):1-4. PubMed ID: 28169606
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Selective neonatal BCG vaccination - a re-audit.
    Venkatesan P; Jayakumar S; Sharief N
    Acta Paediatr; 2007 Jan; 96(1):145-6. PubMed ID: 17187626
    [No Abstract]   [Full Text] [Related]  

  • 45. Selective BCG vaccination in a country with low incidence of tuberculosis.
    Romanus V
    Euro Surveill; 2006; 11(3):14-7. PubMed ID: 16567880
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Vaccination coverage and socioeconomic determinants of BCG vaccination in children before 3 months: Results of the Elfe cohort study, 2011].
    Guthmann JP; Ragot M; Ben Boutieb M; Bois C; Dufourg MN; Lévy-Bruhl D
    Rev Epidemiol Sante Publique; 2016 Sep; 64(4):271-80. PubMed ID: 27553256
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of Bacillus Calmette-Guèrin vaccination at birth and 2 months old age on the peripheral blood T-cell subpopulations [gamma/delta and alpha-beta T cell].
    Taştan Y; Arvas A; Demir G; Alikaşifoğlu M; Gür E; Kiray E
    Pediatr Allergy Immunol; 2005 Dec; 16(8):624-9. PubMed ID: 16343082
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety of intradermal Bacillus Calmette-Guerin vaccine for neonates in Eastern Saudi Arabia.
    Al-Salem AH; Kothari MR; AlHani HM; Oquaish MM; Khogeer SS; Desouky MS
    Saudi Med J; 2012 Feb; 33(2):172-6. PubMed ID: 22327758
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [BCG vaccination in the world].
    Toida I
    Kekkaku; 2000 Jan; 75(1):1-7. PubMed ID: 10689812
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong.
    Leung CC; Tam CM; Chan SL; Chan-Yeung M; Chan CK; Chang KC
    Int J Tuberc Lung Dis; 2001 Aug; 5(8):717-23. PubMed ID: 11495262
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. A statement of the International Union Against Tuberculosis and Lung Disease.
    Tuber Lung Dis; 1994 Jun; 75(3):179-80. PubMed ID: 7919307
    [No Abstract]   [Full Text] [Related]  

  • 52. Targeted TB prevention.
    Carlisle D
    Community Pract; 2005 Nov; 78(11):385-6. PubMed ID: 16317918
    [No Abstract]   [Full Text] [Related]  

  • 53. [Reasons for postponing anti-tuberculosis BCG vaccination of newborn infants].
    Demeshko ND
    Probl Tuberk; 1990; (3):8-10. PubMed ID: 2367513
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The BCG vaccine: information and recommendations for use in Australia.
    National Tuberculosis Advisory Committee
    Commun Dis Intell Q Rep; 2006; 30(1):109-15. PubMed ID: 16637239
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial): a cluster-randomised trial.
    Pereira SM; Barreto ML; Pilger D; Cruz AA; Sant'Anna C; Hijjar MA; Ichihara MY; Santos AC; Genser B; Rodrigues LC
    Lancet Infect Dis; 2012 Apr; 12(4):300-6. PubMed ID: 22071248
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neonatal bacillus Calmette-Guerin vaccination and environmental mycobacteria in sensitizing antimycobacterial activity of macrophages.
    Periasamy M; Datta M; Kannapiran M; Ramanathan VD; Venkatesan P
    Am J Med Sci; 2014 Jul; 348(1):57-64. PubMed ID: 24374737
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BCG vaccination of full-term infants with chronic intrauterine malnutrition: influence of immunization age on development of post-vaccination, delayed tuberculin hypersensitivity.
    Mussi-Pinhata MM; Goncalves AL; Foss NT
    Bull World Health Organ; 1993; 71(1):41-8. PubMed ID: 8440036
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BCG vaccination practices in Victoria.
    Altmann AE; Carnie JA
    Aust N Z J Public Health; 1996 Oct; 20(5):521-4. PubMed ID: 8987224
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neonatal BCG: a time for change.
    Pillay T; Toldi G; Hussain A; Magwenzi MM; Satodia P; Radcliffe R
    Arch Dis Child Educ Pract Ed; 2024 Jan; 109(1):19-24. PubMed ID: 36008111
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acute lower respiratory infection among Bacille Calmette-Guérin (BCG)-vaccinated children.
    Hollm-Delgado MG; Stuart EA; Black RE
    Pediatrics; 2014 Jan; 133(1):e73-81. PubMed ID: 24379224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.